"10.1371_journal.pone.0124109","plos one","2015-04-20T00:00:00Z","Ken Ohta; Masakazu Ichinose; Yuji Tohda; Michael Engel; Petra Moroni-Zentgraf; Satoko Kunimitsu; Wataru Sakamoto; Mitsuru Adachi","National Hospital Organization, Tokyo National Hospital, Tokyo, Japan; Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan; Department of Respiratory Medicine and Allergology, Kinki University, Faculty of Medicine, Osakasayama City, Japan; TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; Clinical Trial Management Department, Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan; Medical Data Services Department, Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan; Department of Clinical Research Center, International University of Health and Welfare, Sanno Hospital, Tokyo, Japan","Conceived and designed the experiments: KO ME PMZ SK WS. Performed the experiments: KO MI YT MA. Analyzed the data: KO MI YT ME PMZ SK WS MA. Wrote the paper: KO MI YT ME PMZ SK WS MA.","The authors have the following interests: this work was supported by Boehringer Ingelheim, the employer of Michael Engel and Petra Moroni-Zentgraf. Satoko Kunimitsu and Wataru Sakamoto are employed by Nippon Boehringer Ingelheim Co., Ltd. All were involved in the study design, analysis and interpretation of the manuscript. Tiotropium Respimat is a Boehringer Ingelheim product. Ken Ohta has served on advisory boards for Boehringer Ingelheim and received lecture fees from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, MSD, Novartis, Astellas, Kyorin and Ono. Masakazu Ichinose has served on advisory boards for Boehringer Ingelheim Pharma GmbH and received lecture fees from Nippon Boehringer Ingelheim Co., Ltd. Yuji Tohda has received lecture fees from Nippon Boehringer Ingelheim Co., Ltd, Kyorin, MSD and TEIJIN Pharma. Mitsuru Adachi has received lecture honoraria from Boehringer Ingelheim, GlaxoSmithKline, Novartis, Astellas, Kyorin, Torii and Kyowa Hakko Kirin Pharma. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2015","04","Ken Ohta","KO",8,TRUE,5,4,8,8,TRUE,TRUE,FALSE,0,NA,FALSE
